Company Overview of Immune Design Corp.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. The company develops various product candidates based on its IMDZVex and GLAAS product discovery platforms. Its oncology clinical-stage product candidates include LV305, G305, and CMB305, which are in Phase-I clinical trials for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma. The company’s oncology clinical-stage product candidates also comprise G100 that is in Phase-I clinical trials for the treatment of patients with merkel cell carcinoma and sarcoma; and in pre-clinical stage f...
1616 Eastlake Avenue East
Seattle, WA 98102
Founded in 2008
Key Executives for Immune Design Corp.
Chief Executive Officer, President and Director
Total Annual Compensation: $798.3K
Principal Financial Officer, Principal Accounting Officer and Executive Vice President of Strategy & Finance
Total Annual Compensation: $433.4K
Chief Medical Officer
Total Annual Compensation: $418.5K
Chief Development Officer
Total Annual Compensation: $378.7K
Compensation as of Fiscal Year 2014.
Immune Design Corp. Key Developments
Immune Design Corp. - Special Call
May 26 15
To discuss post-ASCO Clinical Research Update
Immune Design Corp. Announces Management Changes, Effective May 13, 2015
May 18 15
On May 13, 2015, Paul Rickey, Vice President, Finance and Administration of Immune Design Corp. announced his resignation effective May 31, 2015 from all of his positions with the company, including his positions as Principal Financial Officer and Principal Accounting Officer of the company, in order to pursue other endeavors. The company has hired Christopher Whitmore and appointed him as its Vice President, Finance and Administration effective May 31, 2015. Mr. Whitmore joined the company from AcelRx Pharmaceuticals Inc. Mr. Rickey will remain as a consultant to the company to assist with Mr. Whitmore's transition into his new role. Additionally, on May 13, 2015, the company appointed Stephen R. Brady as the company's Principal Financial Officer and Principal Accounting Officer effective May 31, 2015. Mr. Brady is currently serving as the company's Executive Vice President, Strategy & Finance.
Immune Design Corp. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015
May 14 15
Immune Design Corp. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $1,938,000 against $25,000 a year ago. Loss from operations was $9,406,000 against $5,513,000 a year ago. Net loss attributable to common stockholders was $9,406,000 or $0.56 per basic and diluted share against $8,223,000 or $22.25 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|